Unknown

Dataset Information

0

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.


ABSTRACT: PURPOSE:Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression. Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibiting N-myc signaling, and suppressing tumor growth. PATIENTS AND METHODS:Sixty men were treated with alisertib 50 mg twice daily for 7 days every 21 days. Eligibility included metastatic prostate cancer and at least one: small-cell neuroendocrine morphology; ?50% neuroendocrine marker expression; new liver metastases without PSA progression; or elevated serum neuroendocrine markers. The primary endpoint was 6-month radiographic progression-free survival (rPFS). Pretreatment biopsies were evaluated by whole exome and RNA-seq and patient-derived organoids were developed. RESULTS:Median PSA was 1.13 ng/mL (0.01-514.2), number of prior therapies was 3, and 68% had visceral metastases. Genomic alterations involved RB1 (55%), TP53 (46%), PTEN (29%), BRCA2 (29%), and AR (27%), and there was a range of androgen receptor signaling and NEPC marker expression. Six-month rPFS was 13.4% and median overall survival was 9.5 months (7.3-13). Exceptional responders were identified, including complete resolution of liver metastases and prolonged stable disease, with tumors suggestive of N-myc and Aurora-A overactivity. Patient organoids exhibited concordant responses to alisertib and allowed for the dynamic testing of Aurora-N-myc complex disruption. CONCLUSIONS:Although the study did not meet its primary endpoint, a subset of patients with advanced prostate cancer and molecular features supporting Aurora-A and N-myc activation achieved significant clinical benefit from single-agent alisertib.

SUBMITTER: Beltran H 

PROVIDER: S-EPMC6320304 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran Himisha H   Oromendia Clara C   Danila Daniel C DC   Montgomery Bruce B   Hoimes Christopher C   Szmulewitz Russell Z RZ   Vaishampayan Ulka U   Armstrong Andrew J AJ   Stein Mark M   Pinski Jacek J   Mosquera Juan M JM   Sailer Verena V   Bareja Rohan R   Romanel Alessandro A   Gumpeni Naveen N   Sboner Andrea A   Dardenne Etienne E   Puca Loredana L   Prandi Davide D   Rubin Mark A MA   Scher Howard I HI   Rickman David S DS   Demichelis Francesca F   Nanus David M DM   Ballman Karla V KV   Tagawa Scott T ST  

Clinical cancer research : an official journal of the American Association for Cancer Research 20180919 1


<h4>Purpose</h4>Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop <i>de novo</i> or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression. Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibiting N-myc signaling, and suppressing tumor growth.<h4>Patients and methods</h4>Sixty men were treated with alisertib 50 mg twice daily for 7 days every 21 days. Eligibility included metast  ...[more]

Similar Datasets

| PRJNA486061 | ENA
| PRJNA486062 | ENA
| phs001666 | dbGaP
| S-EPMC5537695 | biostudies-other
| S-EPMC7140108 | biostudies-literature
| S-EPMC4777652 | biostudies-literature
| S-EPMC6401337 | biostudies-literature
| S-EPMC5226583 | biostudies-literature
| S-EPMC7718386 | biostudies-literature
| S-EPMC3867644 | biostudies-literature